President Donald Trump’s administration confirmed Thursday that it has reached a deal with Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.gov, the administration’s new direct-to-consumer website.
Source: MarketWatch
